Hoffmann La Roche Drug Patent Portfolio
Hoffmann La Roche owns 3 orange book drugs protected by 15 US patents Given below is the list of Hoffmann La Roche's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9447089 | Compositions and uses thereof | 06 Jun, 2032 | Active |
| US8741920 | Process for the manufacture of pharmaceutically active compounds | 27 Jul, 2030 | Active |
| US7863288 | NA | 20 Jun, 2029 | Active |
| US7504509 | Compounds and methods for development of Ret modulators | 22 Oct, 2026 | Active |
| US8470818 | NA | 02 Aug, 2026 | Active |
| US8143271 | NA | 21 Jun, 2026 | Active |
| US7192938 | Method of treatment using bisphosphonic acid | 06 May, 2023 | Expired |
| US7410957 | Method of treatment using bisphosphonic acid | 06 May, 2023 | Expired |
| US7718634 | Method of treatment using bisphosphonic acid | 06 May, 2023 | Expired |
| US6352717 | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses | 16 May, 2020 | Expired |
| US6352717 | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses | 16 Nov, 2019 | Expired |
| US6294196 | Pharmaceutical composition containing diphosphonic acid or salt thereof | 07 Oct, 2019 | Expired |
| US6143326 | Oral pharmaceutical preparation containing ibandronat | 21 Apr, 2017 | Expired |
| US6008228 | Pharmaceutical compositions containing proteinase inhibitors | 06 Dec, 2015 | Expired |
| US6008228 | Pharmaceutical compositions containing proteinase inhibitors | 06 Jun, 2015 | Expired |
Latest Legal Activities on Hoffmann La Roche's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Hoffmann La Roche.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2024 | US9447089 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Sep, 2023 | US8143271 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jul, 2022 | US7863288 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8741920 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Dec, 2020 | US8470818 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Sep, 2020 | US7504509 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Mar, 2020 | US9447089 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2019 | US8143271 |
| Post Issue Communication - Certificate of Correction | 22 Jul, 2019 | US9447089 |
|
Expire Patent
Critical
| 22 Apr, 2019 | US7192938 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Nov, 2018 | US7192938 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jul, 2018 | US7863288 |
|
Expire Patent
Critical
| 18 Jun, 2018 | US7718634 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Jan, 2018 | US7718634 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Nov, 2017 | US8741920 |
Hoffmann La Roche Drug Patents' Oppositions Filed in EPO
Hoffmann La Roche drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 29, 2008, by Ratiopharm Gmbh. This opposition was filed on patent number EP03722591A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15171526A | Oct, 2018 | Generics (UK) Ltd | Granted and Under Opposition |
| EP07014362A | Jun, 2018 | ALIUD PHARMA GmbH / STADA Arzneimittel GmbH | Revoked |
| EP07014362A | Oct, 2015 | Gedeon Richter Plc. | Revoked |
| EP07014362A | Oct, 2015 | Hexal AG | Revoked |
| EP07014362A | Oct, 2015 | Actavis Group PTC EHF | Revoked |
| EP07014362A | Oct, 2015 | Generica Ilac Sanayi ve Ticaret A.S. | Revoked |
| EP07014362A | Jun, 2015 | Agrobiogen GmbH Biotechnologie | Revoked |
| EP07014362A | Feb, 2015 | Laboratorios Liconsa, S.A. | Revoked |
| EP07014362A | Jan, 2015 | Glenmark Pharmaceuticals s.r.o. | Revoked |
| EP07014362A | Jan, 2015 | Stada-Arzneimittel Aktiengesellschaft | Revoked |
| EP07014362A | Jan, 2015 | Avansor Pharma Oy | Revoked |
| EP07014362A | Jan, 2015 | Synthon BV | Revoked |
| EP07014362A | Jan, 2015 | G. L. Pharma GmbH | Revoked |
| EP03722591A | Feb, 2011 | Sandoz Farmacêutica, Lda. | Revoked |
| EP03722591A | Jul, 2008 | Synthon BV | Revoked |
| EP03722591A | Jul, 2008 | Gedeon Richter Plc. | Revoked |
| EP03722591A | Jul, 2008 | PLIVA HRVATSKA d.o.o. | Revoked |
| EP03722591A | Jul, 2008 | Generics [UK] Limited | Revoked |
| EP03722591A | Jul, 2008 | Teva Pharmaceutical Industries Ltd. et al. | Revoked |
| EP03722591A | Jul, 2008 | ALFRED, E. TIEFENBACHER GMBH & CO. KG | Revoked |
| EP03722591A | Jul, 2008 | Laboratorios Liconsa, S.A. | Revoked |
| EP03722591A | May, 2008 | Ratiopharm GmbH | Revoked |
Hoffmann La Roche's Family Patents
Hoffmann La Roche Drug List
Given below is the complete list of Hoffmann La Roche's drugs and the patents protecting them.
1. Boniva
Boniva is protected by 5 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7192938 | Method of treatment using bisphosphonic acid |
06 May, 2023
(1 year, 6 months ago)
| Expired |
| US7410957 | Method of treatment using bisphosphonic acid |
06 May, 2023
(1 year, 6 months ago)
| Expired |
| US7718634 | Method of treatment using bisphosphonic acid |
06 May, 2023
(1 year, 6 months ago)
| Expired |
| US6294196 | Pharmaceutical composition containing diphosphonic acid or salt thereof |
07 Oct, 2019
(5 years ago)
| Expired |
| US6143326 | Oral pharmaceutical preparation containing ibandronat |
21 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Boniva's drug page
2. Fortovase
Fortovase is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6352717
(Pediatric)
| Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
16 May, 2020
(4 years ago)
| Expired |
| US6352717 | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
16 Nov, 2019
(5 years ago)
| Expired |
| US6008228
(Pediatric)
| Pharmaceutical compositions containing proteinase inhibitors |
06 Dec, 2015
(8 years ago)
| Expired |
| US6008228 | Pharmaceutical compositions containing proteinase inhibitors |
06 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fortovase's drug page
3. Zelboraf
Zelboraf is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9447089 | Compositions and uses thereof |
06 Jun, 2032
(7 years from now)
| Active |
| US8741920 | Process for the manufacture of pharmaceutically active compounds |
27 Jul, 2030
(5 years from now)
| Active |
| US7863288 | NA |
20 Jun, 2029
(4 years from now)
| Active |
| US7504509 | Compounds and methods for development of Ret modulators |
22 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8470818 | NA |
02 Aug, 2026
(1 year, 8 months from now)
| Active |
| US8143271 | NA |
21 Jun, 2026
(1 year, 6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zelboraf's drug page